Loading patent…
AssigneeAlphyn Biologics, Inc.
InventorsGary Michael PEKOE, Jazmyne Kristyne MINK, Steven Aaron PENTELNIK, Neal G. KOLLER
Estimating the term…
The present disclosure provides for the treatment cystic fibrosis and/or a bacterial infection in a cystic fibrosis patient via the administration to the lungs via inhalation of a pharmaceutical composition comprising a therapeutically effective amount of an extract of the Croton lechleri tree. Also provided are details of studies on the effectiveness of an extract of the Croton lechleri tree on cystic fibrosis and/or a bacterial infection in a cystic fibrosis patient and causative pathogens.
A method of treating a cystic fibrosis and/or a bacterial infection in a cystic fibrosis patient in a subject in need thereof comprising administering to the lungs via inhalation a therapeutically effective amount of a pharmaceutical composition containing filtered latex of Croton lechleri, wherein the Croton lechleri contains at least about 110 PPM of Gallocatechin, at least about 780 PPM of Epigallocatechin, about at least about 1.6 PPM of Catechin at least about 2 PPM of Epicatechin, at least about 45 PPM Taspine, and at least about 0.1 PPM of Dimethylcedrusin, wherein the therapeutically effective amount of filtered latex of Croton lechleri Müll.Arg is about 3 wt % to 90 wt %, and the Croton lechleri has a polydispersity index of about 0.5 to 0.85, wherein the composition is suitable for administration via inhalation.
A pharmaceutical composition comprising a therapeutically effective amount of filtered latex of Croton lechleri Müll.Arg, wherein the Croton lechleri Müll.Arg contains at least about 110 PPM of Gallocatechin, at least about 780 PPM of Epigallocatechin, at least about 1.6 PPM of Catechin, at least about 2 PPM of Epicatechin, at least about 45 PPM Taspine, at least about 0.1 PPM of Dimethylcedrusin and wherein the pharmaceutical composition is suitable for administration to the lungs.
Dependencies are inferred from the claim text.